Details of the Drug

General Information of Drug (ID: DMMBQV3)

Drug Name

Ad5-ENVA-48

Synonyms

Ad26-ENVA-01; Ad5-HVR48-ENVA-01; HIV vaccine (ad35 vector), IAVI/Crucell; Recombinant envelope adenovirus 5 vaccine (HIV infection), Crucell/Harvard Medical School; Adenovirus vector vaccine (HIV infection), IAVI/Crucell/BIDMC/Harvard; HIV vaccine (rAd26 vector), IAVI/Crucell/Beth Israel Deaconess Medical Center/Harvard; HIV vaccine (AdVac, PER.C6), Crucell/IAVI/BIDMC/Harvard

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus-1 infection	1C62	Phase 1	[1]

Drug Type

Vaccine

Cross-matching ID

TTD ID: D0OX1Y

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env)	TTEC2T3	ENV_HV1H2	Not Available	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT00695877) Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults. U.S. National Institutes of Health.
2	A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults. PLoS One. 2012;7(8):e41936.
3	A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16.
4	Clinical pipeline report, company report or official report of MacroGenics.
5	Company report (Inovio)
6	GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway. Retrovirology 2010, 7:20.